Merck: Gonal-f Approved in Japan for Ovulation Induction in Infertile Women
The extended marketing authorization includes Gonal-f in 75 IU (International Units) vial and Gonal-f prefilled pen in 300 IU, 450 IU and 900 IU.
In Japan, Gonal-f has been indicated since 2006 to treat male hypogonadotropic hypogonadism (MHH) in combination with human Chorionic Gonadotropin (hCG), for the induction of spermatogenesis. The supplemental New Drug Application (sNDA) for ovulation induction in females was filed by Merck Serono in October 2008.
GONAL-f is currently approved in 77 countries for the treatment of male infertility and in 100 countries to treat female infertility.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.